Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Avid Bioservices, Inc. (CDMO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
19.69+0.72 (+3.80%)
At close: 04:00PM EDT
19.69 0.00 (0.00%)
After hours: 04:30PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close18.97
Open19.18
Bid19.00 x 1000
Ask20.37 x 800
Day's Range19.01 - 19.82
52 Week Range11.30 - 34.51
Volume658,624
Avg. Volume615,837
Market Cap1.213B
Beta (5Y Monthly)2.11
PE Ratio (TTM)144.78
EPS (TTM)0.14
Earnings DateMar 07, 2022 - Mar 11, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est26.67
  • Insider Monkey

    Is Avid Bioservices (CDMO) a Great Buy?

    Investment management company Laughing Water Capital released its second quarter investor letter 2022, a copy of the same can be downloaded here. In the second quarter, the fund returned -19.4%, which brings the year-to-date return to -29.5%. The letter discussed the reasons for the underperformance of its portfolios. S&P 500 & Russell 2000 also underperformed in […]

  • Benzinga

    Read How Avid Bioservices Fared In Q4

    View more earnings on CDMOSee more from BenzingaNovartis' Tislelizumab Extends Overall Survival In Late-Stage Esophageal Cancer StudyNovartis Resumes Production, Delivery Of Radioligand Therapy MedicinesDon't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Motley Fool

    Avid Bioservices, Inc. (CDMO) Q4 2022 Earnings Call Transcript

    On today's call, we have Nick Green, president and CEO; Dan Hart, chief financial officer; and Matt Kwietniak, Avid's chief commercial officer. Today, we will be providing an overview of Avid Bioservices contract development and manufacturing business, including updates on corporate activities and financial results for the quarter and year ended April 30, 2022.

Advertisement
Advertisement